Skip to content
AnalystLens

Steris 8-K Report, Financial Results (May 11, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 11, 2026
Period End
May 11, 2026
Security
STE
In the record · 2019–202610-K810-Q228-K64

STE filed 8 annual reports (10-K), 22 quarterly reports (10-Q) and 64 current reports (8-K) between 2019 and 2026.

  1. Change in control8-K · Mar ’19Mar ’19
  2. Leadership change8-K · Aug ’21Aug ’21
  3. Restructuring8-K · May ’24May ’24
  4. Leadership change8-K · Aug ’25Aug ’25

01—Abstract

Summary

Summary of the 8-K filed May 11, 2026. Cited figures are marked; the original filing is the authoritative source.

STERIS plc reported fiscal 2026 fourth-quarter and full-year results for the periods ended March 31, 2026, furnished under Item 2.02 of this Form 8-K as Exhibit 99.1.

Full-year revenue from continuing operations rose 9% to $5.9 billiona, and constant currency organic revenue growth was 7%. Fourth-quarter revenue increased 7% to $1.6 billion. As-reported diluted EPS from continuing operations was $7.93 for the year, up from $6.16, and adjusted diluted EPS was $10.17, up from $9.22.

Management described fiscal 2026 as "another record year," citing a diversified customer base and growth in procedure volumes. Cash generation was strong. Net cash provided by operations was $1.34 billionb for fiscal 2026, and free cash flow was $982.9 million, compared with $787.2 million in the prior year.

Cash and cash equivalents rose to $439.6 millionc at March 31, 2026, and long-term indebtedness declined to $1.81 billion from $1.92 billion. The Board approved a new $1 billion share repurchase program to replace the prior authorization.

For fiscal 2027, STERIS guided to as-reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%, with adjusted EPS of $11.10 to $11.30d, an increase of 9-11%. Capital expenditures are expected to be about $375 million, including roughly $60 million over two years for a new sterility assurance plant in Mentor, Ohio, and free cash flow is projected at about $850 million.

02—Key points

Key Highlights

  1. Full-year fiscal 2026 revenue from continuing operations increased 9% to $5.9 billion; constant currency organic revenue growth was 7%.
  2. Fourth-quarter revenue rose 7% to $1.6 billion, with constant currency organic growth of 5%.
  3. Full-year as-reported diluted EPS from continuing operations was $7.93 (vs. $6.16); adjusted diluted EPS was $10.17 (vs. $9.22).
  4. Free cash flow was $982.9 million for fiscal 2026, up from $787.2 million, on net cash from operations of $1.34 billion.
  5. Board approved a new $1 billion share repurchase program replacing the prior authorization.
  6. Fiscal 2027 guidance calls for as-reported revenue growth of 7-8%, adjusted EPS of $11.10-$11.30, and free cash flow of approximately $850 million.
  7. Applied Sterilization Technologies fourth-quarter capital equipment revenue declined 62%, while its service revenue grew 10%.

03—Questions

Frequently Asked Questions

  1. How did STERIS perform in fiscal 2026?

    Revenue from continuing operations increased 9% to $5.9 billion, with constant currency organic growth of 7%. As-reported net income from continuing operations attributable to shareholders was $782.3 million, or $7.93 per diluted share, and adjusted EPS was $10.17.

  2. What is the company's outlook for fiscal 2027?

    STERIS expects as-reported revenue to increase 7-8%, with constant currency organic revenue growth of 6-7%. Adjusted EPS is anticipated at $11.10 to $11.30, assuming an approximately 25% effective tax rate. Capital expenditures are expected to be about $375 million and free cash flow about $850 million.

  3. How did the segments perform in the fourth quarter?

    Healthcare revenue grew 7% to $1.14 billion, with operating income of $283.2 million. Life Sciences revenue rose 9% to $162.9 million, with operating income of $70.6 million. Applied Sterilization Technologies revenue grew 6% to $289.2 million, though its capital equipment revenue declined 62%, and segment operating income was $131.1 million.

  4. What capital return actions did STERIS announce?

    The Board authorized a new program to repurchase up to $1 billion of ordinary shares, replacing the prior authorization. Repurchases may be made through open market transactions, including 10b5-1 plans, and the program may be suspended or discontinued at any time. In fiscal 2026, the company repurchased $235.5 million of shares and paid $241.8 million in cash dividends.

  5. What is the Mentor, Ohio investment?

    Included within planned capital expenditures is a strategic investment to build a new sterility assurance manufacturing plant in Mentor, Ohio. The facility will consolidate existing U.S. production into one center of excellence, is anticipated to be operational by late calendar 2027, and has a total investment of approximately $60 million spread over two years.

04—Continue

← View all 8-K filings